Q2 25 EPS
$7.20
BEAT +0.65%
Est. $7.15
Q2 25 Revenue
$67.18B
BEAT +7.30%
Est. $62.61B
vs S&P Since Q2 25
-11.4%
TRAILING MARKET
CI +2.6% vs S&P +14.0%
Market Reaction
Did CI Beat Earnings? Q2 2025 Results
The Cigna Group delivered a strong second quarter for 2025, posting adjusted earnings of $7.20 per share against a consensus estimate of $7.15, a beat of 0.65%, while revenue climbed 11.0% year-over-year to $67.18 billion, clearing Wall Street's $62.… Read more The Cigna Group delivered a strong second quarter for 2025, posting adjusted earnings of $7.20 per share against a consensus estimate of $7.15, a beat of 0.65%, while revenue climbed 11.0% year-over-year to $67.18 billion, clearing Wall Street's $62.61 billion estimate by 7.30%. The headline growth story was Evernorth Health Services, where adjusted revenues surged 17% to $57.83 billion as Pharmacy Benefit Services expanded rapidly and specialty volume gains accelerated biosimilar adoption across the platform. Cigna Healthcare, meanwhile, faced pressure from the March 2025 divestiture of its Medicare-related businesses to HCSC, which weighed on segment revenues, though the unit's underlying performance held more steady on an adjusted basis. Some observers have flagged lingering uncertainty around PBM regulatory risks, a backdrop that has kept sentiment measured even as the numbers impress. Management reaffirmed its full-year 2025 outlook for consolidated adjusted income from operations of at least $29.60 per share, signaling confidence in the durability of Evernorth's momentum heading into the second half of the year.
Key Takeaways
- • Strong organic growth in Evernorth Health Services, including growth of existing client relationships and strong specialty pharmacy growth
- • Pharmacy Benefit Services adjusted revenues grew 20% from strong organic growth and new business
- • Specialty and Care Services drove 13% adjusted revenue growth from strong specialty volume growth and increased biosimilar adoption
- • Premium rate increases in Cigna Healthcare to cover expected increases in medical costs
- • Improved SG&A expense ratio from 6.1% to 5.1% reflecting business mix shift and strong revenue growth
- • Higher stop loss medical costs pressured Cigna Healthcare MCR to 83.2% from 82.3%
CI YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
CI Revenue by Segment
With YoY comparisons, source: SEC Filings
“Listening, adapting, and innovating to meet the evolving needs of our patients, customers, and clients enables us to deliver meaningful value.”
— David M. Cordani, Q2 2025 Earnings Press Release
CI Earnings Trends
CI vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CI EPS Trend
Earnings per share: estimate vs actual
CI Revenue Trend
Quarterly revenue: estimate vs actual
CI Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $7.79 | — | $68.49B | — |
| Q4 25 BEAT FY | $7.65 | $8.08 | +5.65% | $72.47B | +9.17% |
| FY Full Year | — | $29.84 | — | $274.90B | — |
| Q3 25 BEAT | $7.64 | $7.83 | +2.47% | $69.75B | +4.50% |
| Q2 25 BEAT | $7.15 | $7.20 | +0.65% | $67.18B | +7.30% |
| Q1 25 BEAT | $6.35 | $6.74 | +6.17% | $65.50B | +8.48% |